Basic Information
RNALocate ID: | RLID:01002541 |
RNA Symbol: | hsa-miR-454-3p |
Localization: | Nucleus |
RNA Information
RNA Name: | hsa-miR-454 |
RNA ID: | miRBase:MIMAT0003885 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 24918059 |
Tissue/Cell Line: | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) |
Method: | Microarray |
Description: | Data are collected from supplementary Table S2. MiRNA reads in the subcellular fractions. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002540 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01002542 | Nucleolus | HeLa cells | 23940654 |
RLID:11003516 | Exosome | Serum | 18589210 |
RLID:11003517 | Exosome | Saliva | 19627513 |
RLID:11003518 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11003519 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11003520 | Exosome | Plasma | 23663360 |
RLID-D:11000174 | Exosome | Endothelial cells | |
RLID-D:11000559 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-454-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-51582 |
MNDR | hsa-miR-454-3p | Oral squamous cell carcinoma | MNDR-E-MI-51583 |
MNDR | hsa-miR-454-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-51584 |
MNDR | hsa-miR-454-3p | Lymphoma | MNDR-E-MI-51585 |
MNDR | hsa-miR-454-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-51586 |
MNDR | hsa-miR-454-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-51587 |
MNDR | hsa-miR-454-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-51588 |
MNDR | hsa-miR-454-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-51589 |
MNDR | hsa-miR-454-3p | Her2-receptor positive breast cancer | MNDR-E-MI-51590 |
MNDR | hsa-miR-454-3p | Breast cancer luminal | MNDR-E-MI-51591 |
MNDR | hsa-miR-454-3p | Prostate cancer | MNDR-E-MI-51592 |
MNDR | hsa-miR-454-3p | Gastric cancer | MNDR-E-MI-51593 |
MNDR | hsa-miR-454-3p | Alzheimer disease | MNDR-E-MI-51594 |
MNDR | hsa-miR-454-3p | Intracranial aneurysm | MNDR-E-MI-51595 |
MNDR | hsa-miR-454-3p | Dysautonomia familial | MNDR-E-MI-51596 |
MNDR | hsa-miR-454-3p | Myotonic dystrophy | MNDR-E-MI-51597 |
MNDR | hsa-miR-454-3p | Seizures | MNDR-E-MI-51598 |
MNDR | hsa-miR-454-3p | Leukemia | MNDR-E-MI-51599 |
MNDR | hsa-miR-454-3p | Cardiovascular disease | MNDR-E-MI-51600 |
MNDR | hsa-miR-454-3p | Lung cancer | MNDR-E-MI-51601 |
MNDR | hsa-miR-454-3p | Parkinson disease | MNDR-E-MI-51602 |
MNDR | hsa-miR-454-3p | Basal-like breast cancer | MNDR-E-MI-51603 |
MNDR | hsa-miR-454-3p | Pancreatic cancer | MNDR-E-MI-51604 |
MNDR | hsa-miR-454-3p | Melanoma | MNDR-E-MI-51605 |
MNDR | hsa-miR-454-3p | Nephroblastoma | MNDR-E-MI-51606 |
MNDR | hsa-miR-454-3p | Colon cancer | MNDR-E-MI-51607 |
MNDR | hsa-miR-454-3p | Ischemic attack transient | MNDR-E-MI-51608 |
MNDR | hsa-miR-454-3p | Colon adenocarcinoma | MNDR-E-MI-51609 |
MNDR | hsa-miR-454-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-51610 |
MNDR | hsa-miR-454-3p | Ovarian cancer | MNDR-E-MI-51611 |
MNDR | hsa-miR-454-3p | Prostate adenocarcinoma | MNDR-E-MI-51612 |
MNDR | hsa-miR-454-3p | Carcinoma ductal breast | MNDR-E-MI-51613 |
MNDR | hsa-miR-454-3p | Glioblastoma | MNDR-E-MI-51614 |
MNDR | hsa-miR-454-3p | Glioma | MNDR-E-MI-51615 |
MNDR | hsa-miR-454-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-51616 |
MNDR | hsa-miR-454-3p | Breast carcinoma | MNDR-E-MI-51617 |
MNDR | hsa-miR-454-3p | Bone-invasive pituitary adenoma | MNDR-E-MI-51618 |
MNDR | hsa-miR-454-3p | Lung squamous cell carcinoma | MNDR-E-MI-51619 |
MNDR | hsa-miR-454-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-51620 |
MNDR | hsa-miR-454-3p | Lung adenocarcinoma | MNDR-E-MI-51621 |
MNDR | hsa-miR-454-3p | Bladder urothelial carcinoma | MNDR-E-MI-51622 |
MNDR | hsa-miR-454-3p | Pancreatic adenocarcinoma | MNDR-E-MI-51623 |
MNDR | hsa-miR-454-3p | Cervical cancer | MNDR-E-MI-51624 |
MNDR | hsa-miR-454-3p | Kidney renal clear cell carcinoma | MNDR-E-MI-51625 |
MNDR | hsa-miR-454-3p | Renal carcinoma | MNDR-E-MI-51626 |
MNDR | hsa-miR-454-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-51627 |
MNDR | hsa-miR-454-3p | Renal clear cell carcinoma | MNDR-E-MI-51628 |
MNDR | hsa-miR-454-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-51629 |
MNDR | hsa-miR-454-3p | Cholangiocarcinoma | MNDR-E-MI-51630 |
MNDR | hsa-miR-454-3p | Esophageal cancer | MNDR-E-MI-51631 |
MNDR | hsa-miR-454-3p | Lung small cell carcinoma | MNDR-E-MI-51632 |
MNDR | hsa-miR-454-3p | Synovial sarcoma | MNDR-E-MI-51633 |
MNDR | hsa-miR-454-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-51634 |
MNDR | hsa-miR-454-3p | Breast invasive carcinoma | MNDR-E-MI-51635 |
MNDR | hsa-miR-454-3p | Hepatocellular carcinoma | MNDR-E-MI-51636 |
MNDR | hsa-miR-454-3p | B-cell lymphoma | MNDR-E-MI-51637 |
MNDR | hsa-miR-454-3p | Rheumatoid arthritis | MNDR-E-MI-51638 |
MNDR | hsa-miR-454-3p | Malignant pleural mesothelioma | MNDR-E-MI-51639 |
MNDR | hsa-miR-454-3p | Hodgkin lymphoma | MNDR-E-MI-51640 |
MNDR | hsa-miR-454-3p | Neuromyelitis optica | MNDR-E-MI-51641 |
MNDR | hsa-miR-454-3p | Colorectal cancer | MNDR-E-MI-51642 |
MNDR | hsa-miR-454-3p | Nasopharynx carcinoma | MNDR-E-MI-51643 |
MNDR | hsa-miR-454-3p | Multiple myeloma | MNDR-E-MI-51644 |
MNDR | hsa-miR-454-3p | Nasopharyngeal cancer | MNDR-E-MI-51645 |
MNDR | hsa-miR-454-3p | Prostatic neoplasms | MNDR-E-MI-51646 |
MNDR | hsa-miR-454-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-51647 |
MNDR | hsa-miR-454-3p | Stroke lacunar | MNDR-E-MI-51648 |
MNDR | hsa-miR-454-3p | Breast cancer her3+ negative | MNDR-E-MI-51649 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CCDC6 | Homo sapiens | RR00291340 |
TOP